FDA's Single-Study Drug Approval Policy Poised to Trigger Legal Battles and Industry Transformation

The Regulatory Earthquake at America's Drug Watchdog

The FDA has announced a fundamental shift in pharmaceutical regulation that reverses decades of scientific consensus. FDA Commissioner Dr. Marty Makary and deputy Dr. Vinay Prasad revealed in a New England Journal of Medicine article published February 18, 2026, that the agency will now accept a single clinical trial as the "default position" for approving new drugs, abandoning the longstanding two-study requirement that has been a cornerstone of drug safety evaluation. According to Articles 1-6, this policy represents the latest in a series of aggressive deregulatory moves by Makary since his appointment in April 2025, including mandating AI use by FDA staff and offering one-month "fast-track" reviews for drugs serving "national interests." The justification offered is that modern drug research has become "increasingly precise and scientific," making the two-trial standard obsolete.

What This Means: The Immediate Landscape

The policy change fundamentally alters the risk-benefit calculus in pharmaceutical development. Historically, the two-study requirement served as a replication safeguard—protecting against statistical flukes, researcher bias, and population-specific effects that might not generalize. Single positive studies, even well-designed ones, have repeatedly failed to replicate in medical research, a phenomenon that has plagued fields from cancer treatment to psychology. The timing is particularly significant. As noted across all articles, this deregulatory push contrasts sharply with the administration's "more restrictive approach to other products, including vaccines," suggesting a politically-driven rather than scientifically-driven regulatory philosophy.

Prediction 1: Legal Challenges Within Months

The most immediate consequence will be coordinated legal challenges from public health organizations, consumer advocacy groups, and potentially state attorneys general. The Administrative Procedure Act requires federal agencies to provide reasoned explanations for policy changes, particularly those reversing long-established safety standards. Expect lawsuits filed within 60-90 days arguing that: 1. The FDA failed to follow proper rulemaking procedures 2. The change is arbitrary and capricious given the scientific consensus on replication 3. The policy violates the FDA's statutory mandate to ensure drug safety and efficacy These legal challenges will likely succeed in at least temporarily blocking implementation for certain drug categories, particularly those with high toxicity risks or narrow therapeutic windows.

Prediction 2: Pharmaceutical Industry Bifurcation

The pharmaceutical industry will split into two camps within 6-12 months. Major established pharmaceutical companies (Pfizer, Merck, Johnson & Johnson) will likely continue conducting two or more trials for most products to: - Maintain international market access (European Medicines Agency and other regulators are unlikely to follow suit) - Protect against liability in the inevitable adverse event lawsuits - Preserve scientific credibility and institutional reputation Meanwhile, smaller biotech firms and venture-backed startups will aggressively exploit the single-study pathway, creating a two-tier system where drugs from smaller, less-established companies enter the market with significantly less evidence. This will accelerate the "move fast and break things" ethos into pharmaceutical development—with potentially deadly consequences.

Prediction 3: High-Profile Drug Safety Crisis Within 18-24 Months

The statistical reality of single-study approvals makes a major drug safety incident nearly inevitable. When a drug approved on single-study evidence causes unexpected deaths or serious adverse events in the broader population, it will trigger: - Congressional hearings and potential legislative action to reverse the policy - Massive tort litigation against both the manufacturer and potentially the FDA - A crisis of public confidence in pharmaceutical regulation - Calls for Makary's resignation or removal The FDA's traditional two-study requirement exists precisely because individual studies—even large, well-designed ones—regularly produce false positives or miss safety signals that only emerge with replication and larger populations.

Prediction 4: International Regulatory Divergence

Within the next year, expect explicit statements from the European Medicines Agency, Health Canada, and other major regulatory bodies distancing themselves from the FDA's approach. This will: - Create a competitive disadvantage for FDA-approved drugs in international markets - Force companies developing for global markets to conduct multiple studies anyway - Potentially position the EU as the new "gold standard" in pharmaceutical regulation - Undermine the FDA's century-long reputation as the world's most rigorous drug regulator

The Political Dimension

The contrast between accelerated approval for pharmaceuticals while restricting vaccines suggests this policy serves political rather than scientific objectives. This politically-motivated regulatory approach will likely face resistance from career FDA scientists, potentially leading to high-profile resignations and whistleblower complaints within 3-6 months.

Conclusion: A Dangerous Experiment

The FDA's single-study policy represents a massive deregulatory experiment with the American public as unwitting test subjects. While proponents argue it will speed access to beneficial treatments, the abandonment of replication standards contradicts fundamental principles of scientific evidence. The most likely outcome is a period of increased drug approvals followed by a preventable public health crisis that forces policy reversal—but only after significant harm has occurred. The question is not whether this policy will fail, but how many people will be injured before it does.